This bill treats xylazine—which is used legally in veterinary medicine but increasingly appears in illicit human drug markets—as a federally controlled substance and narrows lawful possession to dispensed veterinary uses and certain government animal programs. It also directs federal agencies to improve tracking and to review sentencing for xylazine‑related offenses.
Professionals in veterinary care, pharmaceutical manufacturing, drug enforcement, and public‑health surveillance should care because the measure restructures legal access, imposes new reporting expectations on the supply chain, and creates transition rules that will affect how manufacturers, pharmacies, and practitioners handle existing inventory and registrations.
At a Glance
What It Does
The bill adds xylazine (including salts and isomers) into the Controlled Substances Act and treats material containing any quantity as controlled. It restricts who counts as an 'ultimate user' for xylazine—limiting lawful possession largely to animals and authorized animal programs—and requires federal tracking and agency coordination to implement the change.
Who It Affects
Veterinarians and veterinary pharmacies, manufacturers of xylazine, animal control and wildlife agencies, federal and state law enforcement agencies, and the Drug Enforcement Administration and Food and Drug Administration as implementers.
Why It Matters
By folding xylazine into federal control and adding supply‑chain reporting, the bill aims to make diversion easier to detect and prosecute while protecting legitimate animal uses—creating compliance obligations across the veterinary supply chain and new data streams for public‑health responders.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill begins by inserting a statutory definition of xylazine into the Controlled Substances Act that expressly captures the base compound and any of its salts or isomers. Rather than leaving practical access open, it moves to treat any material that contains xylazine as a controlled product under the Act.
That change is implemented by placing xylazine under Schedule III of the Controlled Substances Act, which triggers the Act’s regulatory framework for manufacture, distribution, and enforcement.
Because xylazine is an accepted veterinary sedative, the bill rewrites the 'ultimate user' definition for this substance alone: lawful possession is limited to people who obtained it from a registered veterinarian or pharmacy on a veterinarian’s prescription, and only for animal ownership, animal care, or government animal/wildlife programs. The change explicitly includes agencies and businesses with animals and their employees acting within scope, and it clarifies that such end‑users do not themselves need DEA registration to possess xylazine lawfully under those enumerated uses.Recognizing the practical disruptions of rescheduling, the bill phases in many compliance requirements.
It waives immediate capital security upgrades for manufacturers that already produce xylazine; defers labeling, packaging, and distribution rules for one year; and delays practitioner registration, inventory, and record‑keeping obligations for 60 days, allowing practitioners who apply for registration during that period to continue lawful activity while the application is pending. The text also directs the FDA and DEA to expedite manufacturer submissions related to this change so firms can transition regulatory paperwork more quickly.To close information gaps, the bill amends the ARCOS reporting statute to include xylazine so the DEA receives data on transactions of legally distributed xylazine products.
It instructs the United States Sentencing Commission to review and, if appropriate, amend guidelines for offenses involving xylazine and requires the Attorney General (through the DEA and in coordination with the FDA) to report to Congress on prevalence, diversion sources, origin points, and potential analogues—an initial report due in 18 months and an update due in four years.
The Five Things You Need to Know
The bill adds xylazine (and its salts and isomers) to Schedule III, making any material that contains xylazine a controlled substance under federal law.
For xylazine only, the bill redefines 'ultimate user' so lawful possession is limited to material dispensed by a registered veterinarian or a registered pharmacy on a veterinarian’s prescription and only for animal ownership, animal care, or authorized government animal/wildlife programs.
Manufacturers that already produce xylazine are exempted from immediate capital security upgrade requirements tied to Schedule III manufacturing, while labeling/packaging rules are delayed for one year and practitioner registration/inventory rules are delayed for 60 days.
The bill requires adding xylazine to ARCOS reporting so distributors and manufacturers must report transactions to the DEA, and it directs FDA and DEA to expedite manufacturer submissions and applications related to the rescheduling.
The United States Sentencing Commission must review sentencing guidelines for xylazine offenses, and the Attorney General (via DEA and FDA) must deliver an 18‑month report and a four‑year update to Congress on diversion, origins, and the existence of analogues.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Statutory definition added for xylazine
This section inserts a new definition into the Controlled Substances Act that explicitly covers xylazine along with its salts and isomers. Practically, that language is broad by design: it prevents simple chemical tweaks from escaping the statutory term and provides a legal hook for enforcement against closely related variants.
Placement of xylazine in Schedule III
The bill amends Schedule III to list any material containing xylazine. That placement brings xylazine under the CSA’s manufacture/distribution/regulatory regime rather than leaving it unregulated at the federal controlled‑substance level; businesses will consequently face standard scheduling obligations unless the bill’s transition provisions modify timing.
Tailored 'ultimate user' definition and transition rules
This is the operational core for legitimate access. It narrows lawful, non‑registered possession to recipient animals and specified government uses and includes entities and employees acting within the scope of their duties. The same section provides multiple transition mechanisms: manufacturers are temporarily exempt from immediate capital security expenditures, labeling/packaging/distribution requirements are deferred one year, practitioner registration and recordkeeping rules are deferred 60 days, and FDA/DEA are directed to help expedite manufacturer paperwork.
Add xylazine to ARCOS and adjust statutory references
Section 5 updates the ARCOS reporting provisions so xylazine transactions are reported into the DEA’s automated system. It also aligns cross‑references to FDA approval provisions, linking controlled‑substance reporting to FDA regulatory status where relevant. This mechanically creates a federal data trail for legally produced and distributed xylazine.
Sentencing Commission review
The Sentencing Commission receives a directive to review sentencing rules for offenses involving xylazine and consider its common forms and co‑use with other schedules. The directive does not mandate specific guideline changes, but it signals congressional intent that penalties be examined and adjusted where appropriate to reflect the rescheduling.
Congressional reporting requirements
The Attorney General, through DEA and coordinated with FDA, must report to Congress on illicit xylazine prevalence and impacts—initially within 18 months and then again at four years. The reports must address diversion pathways, origins, and whether analogues present substantial abuse risks, which will inform enforcement and any subsequent statutory adjustments.
This bill is one of many.
Codify tracks hundreds of bills on Justice across all five countries.
Explore Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Veterinary practices and authorized animal programs: The bill explicitly preserves legal animal uses of xylazine and includes employees and agencies acting within scope, reducing risk that routine veterinary activity will be criminalized if practitioners follow the dispensing pathways described.
- Law enforcement and public‑health surveillance agencies: Adding xylazine to ARCOS and requiring interagency reports gives investigators and epidemiologists better transaction data and structured intelligence on diversion and origin points.
- Manufacturers with existing production lines: The temporary waiver of immediate capital security expenditures and the instruction for FDA/DEA to expedite submissions lowers upfront compliance costs and smooths the transition to a scheduled framework.
- Wildlife management and government animal‑control programs: The statute explicitly authorizes possession and use for government animal programs, protecting operational access for population control and wildlife care.
Who Bears the Cost
- Veterinarian offices and veterinary pharmacies: They will need to comply with Schedule III dispensing rules after the transition windows, including eventual recordkeeping, secure storage, and possibly new registration and inventory procedures—raising administrative and training costs.
- Distributors and pharmacies handling veterinary drugs: Inclusion in ARCOS and Schedule III triggers transaction reporting, altered distribution logistics, and later labeling/packaging compliance that increase compliance workloads and potentially slow distribution timelines.
- DEA and FDA (implementation workload): Both agencies must process expedited manufacturer submissions, add xylazine to tracking systems, coordinate enforcement guidance, and support reporting to Congress, creating an unfunded or underfunded administrative burden.
- Courts and prosecutors: If the Sentencing Commission recommends guideline changes and enforcement ramps up, state and federal prosecutors will see new charging decisions and potentially more prosecutions involving xylazine, creating caseload pressure.
Key Issues
The Core Tension
The central dilemma is restricting access enough to curb diversion and protect public health while not erecting barriers that hamper legitimate veterinary care and impose disproportionate costs on animal health providers and the regulated supply chain; the bill favors targeted supply‑chain controls and reporting, but those controls shift the burden of detection and compliance upstream, where implementation is administratively and legally complex.
The bill balances two priorities—shutting down illicit human use and preserving legitimate veterinary access—but it leaves several implementation knots. Defining lawful possession tightly around veterinarian‑dispensed material reduces ambiguity for animal care, yet it increases the enforcement focus on the supply chain: diversion will likely occur upstream (manufacturers, distributors, clinics) and may require sustained ARCOS analysis to detect.
ARCOS will capture legal transactions but will not directly measure illicit batches created outside the licit supply chain, so the reporting requirement improves visibility without eliminating black‑market production risks.
The transition provisions blunt immediate disruption for manufacturers and practitioners, but staggered compliance deadlines create a temporary compliance asymmetry—some obligations apply sooner than others—potentially producing enforcement gray areas during the first year. Asking FDA and DEA to 'expedite' submissions helps, but statutory authority and resource constraints will determine how quickly manufacturers receive needed approvals.
The Sentencing Commission review and the multi‑year reporting cadence aim to inform policy, but both depend on quality data; if diversion patterns shift rapidly or analogues proliferate, the timing of these reviews may lag the operational reality. Lastly, the broad catch‑all in the definition (salts and isomers) strengthens enforcement reach against chemically modified compounds but could invite legal challenges over novel analogues or prosecutorial scope.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.